Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial
(2003) In Clinical Infectious Diseases 37(3). p.333-340- Abstract
- The efficacy and safety of high-dose intravenous polyspecific immunoglobulin G (IVIG) as adjunctive therapy in streptococcal toxic shock syndrome (STSS) were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. The trial was prematurely terminated because of slow patient recruitment, and results were obtained from 21 enrolled patients (10 IVIG recipients and 11 placebo recipients). The primary end point was mortality at 28 days, and a 3.6-fold higher mortality rate was found in the placebo group. A significant decrease in the sepsis-related organ failure assessment score at days 2 (P = .02) and 3 (P = .04) was noted in the IVIG group. Furthermore, a significant increase in plasma neutralizing activity against... (More)
- The efficacy and safety of high-dose intravenous polyspecific immunoglobulin G (IVIG) as adjunctive therapy in streptococcal toxic shock syndrome (STSS) were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. The trial was prematurely terminated because of slow patient recruitment, and results were obtained from 21 enrolled patients (10 IVIG recipients and 11 placebo recipients). The primary end point was mortality at 28 days, and a 3.6-fold higher mortality rate was found in the placebo group. A significant decrease in the sepsis-related organ failure assessment score at days 2 (P = .02) and 3 (P = .04) was noted in the IVIG group. Furthermore, a significant increase in plasma neutralizing activity against superantigens expressed by autologous isolates was noted in the IVIG group after treatment (P = .03). Although statistical significance was not reached in the primary end point, the trial provides further support for IVIG as an efficacious adjunctive therapy in STSS. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/900117
- author
- Darenberg, J ; Ihendyane, N ; Sjolin, J ; Aufwerber, E ; Haidl, Sven LU ; Follin, P ; Andersson, J and Norrby-Teglund, A
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Infectious Diseases
- volume
- 37
- issue
- 3
- pages
- 333 - 340
- publisher
- Oxford University Press
- external identifiers
-
- pmid:12884156
- wos:000184407900003
- scopus:0041402681
- ISSN
- 1537-6591
- DOI
- 10.1086/376630
- language
- English
- LU publication?
- yes
- id
- 33f28498-a21c-4860-977c-af8157750891 (old id 900117)
- date added to LUP
- 2016-04-01 11:46:56
- date last changed
- 2022-03-20 18:49:58
@article{33f28498-a21c-4860-977c-af8157750891, abstract = {{The efficacy and safety of high-dose intravenous polyspecific immunoglobulin G (IVIG) as adjunctive therapy in streptococcal toxic shock syndrome (STSS) were evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. The trial was prematurely terminated because of slow patient recruitment, and results were obtained from 21 enrolled patients (10 IVIG recipients and 11 placebo recipients). The primary end point was mortality at 28 days, and a 3.6-fold higher mortality rate was found in the placebo group. A significant decrease in the sepsis-related organ failure assessment score at days 2 (P = .02) and 3 (P = .04) was noted in the IVIG group. Furthermore, a significant increase in plasma neutralizing activity against superantigens expressed by autologous isolates was noted in the IVIG group after treatment (P = .03). Although statistical significance was not reached in the primary end point, the trial provides further support for IVIG as an efficacious adjunctive therapy in STSS.}}, author = {{Darenberg, J and Ihendyane, N and Sjolin, J and Aufwerber, E and Haidl, Sven and Follin, P and Andersson, J and Norrby-Teglund, A}}, issn = {{1537-6591}}, language = {{eng}}, number = {{3}}, pages = {{333--340}}, publisher = {{Oxford University Press}}, series = {{Clinical Infectious Diseases}}, title = {{Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial}}, url = {{http://dx.doi.org/10.1086/376630}}, doi = {{10.1086/376630}}, volume = {{37}}, year = {{2003}}, }